Use of antibiotics for urinary tract infection in women undergoing surgery for urinary incontinence: a cohort study

Rikke Guldberg,1,2 Ulrik Schiøler Kesmodel,3 Søren Brostrøm,4 Linda Kærlev,1,2 Jesper Kjær Hansen,1,2 Jesper Hallas,5 Bente Mertz Norgård1,2

ABSTRACT

Objective: To describe the use of antibiotics for urinary tract infection (UTI) before and after surgery for urinary incontinence (UI); and for those with use of antibiotics before surgery, to estimate the risk of treatment for a postoperative UTI, relative to those without use of antibiotics before surgery.

Design: A historical population-based cohort study.

Setting: Denmark.

Participants: Women (age ≥18 years) with a primary surgical procedure for UI from the county of Funen and the Region of Southern Denmark from 1996 throughout 2010. Data on redeemed prescriptions of antibiotics ±365 days from the date of surgery were extracted from a prescription database.

Main outcome measures: Use of antibiotics for UTI in relation to UI surgery, and the risk of being a postoperative user of antibiotics for UTI among preoperative users.

Results: A total of 2151 women had a primary surgical procedure for UI; of these 496 (23.1%) were preoperative users of antibiotics for UTI. Among preoperative users, 129 (26%) and 215 (43.3%) also redeemed prescriptions of antibiotics for UTI within 0–60 and 61–365 days after surgery, respectively. Among preoperative non-users, 182 (11.0%) and 235 (14.2%) redeemed prescriptions within 0–60 and 61–365 days after surgery, respectively. Presurgery exposure to antibiotics for UTI was a strong risk factor for postoperative treatment for UTI, both within 0–60 days (adjusted OR, aOR=2.6 (95% CI 2.0 to 3.5)) and within 61–365 days (aOR=4.5 (95% CI 3.5 to 5.7)).

Conclusions: In 4 women undergoing surgery for UI, 1 was treated for UTI before surgery, and half of them had a continuing tendency to UTIs after surgery. Use of antibiotics for UTI before surgery was a strong risk factor for antibiotic use after surgery. In women not using antibiotics for UTI before surgery only a minor proportion initiated use after surgery.

INTRODUCTION

Urinary tract infection (UTI) is a common problem in women, and 40% of women have UTI during their lifetime—of these, 27% have recurrent UTI within 12 months.1 There are several risk factors for UTI and recurrent UTI; for example, high age, urogenital atrophy and urinary incontinence (UI).2 3 UI is associated with UTI,4 5 and UTI might be regarded as a comorbid condition in women with UI due to several factors including poor perineal hygiene.5 Thus, it is not surprising that UTI is seen in women with UI, but no studies have so far examined the burden of UTI in women undergoing surgery for UI in a population-based setting.

It is also well known that UTI is common after UI surgery. Risk factors of postoperative UTI include previous recurrent UTI, postoperative catheterisation, positive urine cultures at day of surgery and preoperative postvoid residual.6 7 UTI after UI surgery might occur among 6–38% of the women—depending on diagnostic methods and criteria.8 9 10–16 and surgery-related infections occur within 2 months.17 Thus, while some knowledge of UTI exists in the short-term perspective after UI surgery, there is only little evidence on the frequency of UTI in a more long-term perspective after UI surgery.8

The purpose of this study was to examine the use of antibiotics for UTI before and

Strengths and limitations of this study

- A population-based study.
- 2151 included women.
- High quality of data sources and complete information in the follow-up period for all included women.
- Adjustment for several factors: age, procedure type, preoperative oestrogen use, comorbidity, educational level and personal annual income.
- Redeemed prescriptions were used as a proxy for drug use.
- No data on symptomatology, catheter usage, preoperative antibiotics or urine culture.
after surgery for UI, and among women using antibiotics for UTI before surgery to estimate the risk of postoperative use in a short-term and long-term perspective. This topic is clinically highly relevant in the counselling of women prior to surgery for UI: What can they expect of postoperative complications? Can preoperative drug users expect to continue drug use after surgery?

MATERIALS AND METHODS

Study population and settings
Women were included in the study if they had a primary surgical procedure for UI within the period of 1 January 1996 through 31 December 2010. Data on performed procedures were retrieved from the Danish National Patient Registry (NPR)18 according to codes listed in online supplementary appendix 1. The surgical procedures were performed in one of four hospitals in the county of Funen, Denmark, between 1 January 1996 and 31 December 2006 or for the period 2007 through 2010 in 1 of 13 hospitals in the new Region of Southern Denmark (including Funen). The extension of the area was due to a change in the organisation of the healthcare system in 2007, including a structural change from 14 counties to 5 regions. Women with concomitant or prior surgery for pelvic organ prolapse were included. Women younger than 18 years were excluded.

Data sources
Data for this study were retrieved from three Danish registries: the NPR, Odense University Pharmacoepidemiologic Database (OPED), the Statistics Denmark. All Danish citizens are assigned a unique Civil Registration Number (CRN), which enables individual-level linkage across registries.19

The NPR contains data on discharges from public hospitals in Denmark, and the completeness of recordings has been estimated to be 99.4%.20 Information available in the registry pertain to the CRN, the dates of admission, dates of discharge and discharge diagnoses, classified according to the International Classification of Diseases-8 (ICD-8) (1977–1993) and ICD-10 (1994 and onward)21 22 as well as codes from the Danish classification system of surgical procedures.23

Information on relevant drugs (antibiotics and oestrogens) was retrieved from the OPED for the period 1995 to 2011 for the entire study population.

The OPED is pharmacy-based and captures all reimbursed prescriptions, and contains person-identifiable data with complete coverage on all computerised prescription reimbursements from the county of Funen (population 2006: 479 000) from 1990 and from January 2007 onwards extended to the whole Region of Southern Denmark (population 1.2 million). The age and gender distribution of this population is very similar to that of the Danish population as a whole (2006: 5.4 million), and the prescribing of drugs is very similar to the national average.24

Prescription reimbursements are given independent of patient income to all legal inhabitants of Denmark as a part of the National Health Service. Each record includes the CRN, date of purchase, a full account of what have been dispensed, including the brand name and the Anatomical Therapeutic Chemical (ATC) classification code. Information not included in the prescription database is drugs sold over the counter or drugs not reimbursed by the county authority (mainly oral contraceptives, sedatives and hypnotics). Data on highest attained educational level and annual income were retrieved from the Danish Integrated Database for Labour Market Research at Statistics Denmark, a database with annually updated socioeconomic data for each Danish citizen, mainly supplied by tax authorities, educational institutions and employment services.25

Antibiotics under study
Included drugs were antibiotics traditionally used in Denmark exclusively or predominantly for the treatment of UTI (sulphanmethizole (ATC J01EB02), pivmecillinam (ATC J01CA08), nitrofurantoin (ATC J01XE01), trimethoprim (ATC J01EA01), as well as mecillinam (ATC J01CA11))26 27 and with a duration of 3–5 days. The indications for the prescribed drugs are not registered in the OPED; therefore, pivampicillin and amoxicillin were not included—as these antibiotics are also commonly used in treatment of upper respiratory tract infections. Likewise, broader spectrum antibiotics such as cephalosporins and quinolones were not included, as they are not commonly used for UTIs in Denmark.

Exposed and unexposed cohorts
Exposed cohort: All women ≥18 years undergoing a primary surgical procedure for UI between 1 January 1996 and 31 December 2010 in the county of Funen/Region of Southern Denmark, and having redeemed one or more prescriptions on antibiotics within 365 days preceding the date of surgery (index date).

Unexposed cohort: All women ≥18 years undergoing a primary surgical procedure for UI between 1 January 1996 and 31 December 2010 in the county of Funen/Region of Southern Denmark without having redeemed similar prescriptions within the same time frame.

Outcome data
For both exposed and unexposed women, the outcome was use of antibiotics for UTI, defined as having redeemed at least one prescription for these antibiotics within (1) 60 days after the index date (short-term postoperative users) and (2) 61–365 days after the index date (long-term postoperative users). These outcomes were not mutually exclusive, that is, a woman might be classified as a short-term and long-term user, postoperatively.
Covariates
The use of antibiotics might be affected by age, type of surgery, use of oestrogen, comorbidity, calendar time and the individuals’ ability to pay for the medicine might be affected by educational level and annual income. Therefore, these variables were included in the analysis as potential confounders.

Type of procedures
The types of UI surgery were divided into four groups according to the surgical procedure code: (1) mid-urethral sling procedures with transobturator route (toMUS), (2) mid-urethral sling procedures with retropubic route (rpMUS), (3) bulking procedures and (4) other types of UI surgeries.

Oestrogen
Use of oestrogens (ATC G03C) was included in the analyses as a confounder.

To adjust for preoperative oestrogen use, preoperative users of oestrogens were defined as women who had redeemed at least one prescription for oestrogens within 365 days preceding the date of surgery and nonusers were defined as those who had no preoperative oestrogen use during the same period. The local and systemic oestrogens were included.

Comorbidity
The comorbidity was classified according to the validated, well-known and widely used Charlson comorbidity index (CCI), which assigns different weights (1, 2, 3 and 6) to 20 different disease categories specified by medical condition and severity (eg, diabetes, cardiovascular diseases, chronic pulmonary, renal, liver and connective tissue diseases). The CCI was computed based on each woman’s complete hospital discharge history from the NPR since 1977. A categorised version of the CCI score values was used: 0 (low), 1–2 (medium) and 3+ (high).32

Education and income
Information on educational level and annual income for each woman was retrieved as a measure of socio-economic status. Educational level was categorised into four groups: (1) basic school, (2) high school, (3) vocational education, (4) basic school/high school education, (5) high school, (6) higher education or university level. The income was averaged for the five years before surgery and categorised as low (25%–50%), medium (50%–75%) and high income (75%–100%).

Statistical analysis
The use of antibiotics for UTI within the first 365 days after surgery for exposed and unexposed cohorts was illustrated in a flow chart. We also constructed contingency tables for the main study variables, and computed ORs, with 95% CIs.

To analyse the significance of preoperative antibiotic use as risk factor of postoperative use (within 60 days and within 61–365 days after surgery), adjusted ORs were estimated by means of multivariate logistic regression models.

Adjustment was made for age (18–39, 40–59 and ≥60 years (reference)), type of procedures (toMUS (reference), rpMUS, bulking, others), education (basic (reference), secondary, higher), annual income (low (reference), middle, high), comorbidity (CCI 0 (reference), CCI 1–2, CCI 3+), calendar year (1996–2006, 2007–2008 (reference), 2009–2010) and use of oestrogen within 365 days preceding the date of surgery (no (reference), yes).

Stratified analyses were performed according to the use of oestrogens before surgery to examine the association between the use of antibiotics for UTI in oestrogen users versus oestrogen non-users.

All analyses were performed using Stata Release 12.0.

RESULTS
A total of 2151 women had a primary surgical procedure for UI between 1 January 1996 and 31 December 2010; 2073 had a solitary UI surgery, and 78 had concomitant surgery for pelvic organ prolapse.

Of the 2151 women, 1655 (76.9%) women did not use antibiotics for UTI within 365 days preceding the date of surgery, while 496 (23.1%) did, and the majority (376/496=75.8%) redeemed ≤2 prescriptions preoperatively and only a minority (42/496=8%) redeemed more than five or more prescriptions. The use of antibiotics for UTI within 365 days after surgery is detailed for the exposed and unexposed cohorts in figure 1. The most commonly used antibiotics both preoperatively and postoperatively were sulphasemidol and pivmecillinam.

Women having redeemed prescriptions for antibiotics for UTI before surgery (exposed)
Of the 496 women with prior use of antibiotics for UTI, 129 (26%) redeemed a prescription for antibiotics for UTI within 0–60 days after surgery, and of these, 85 (65.9%) also within 61–365 days after surgery (figure 1). A total of 215 (43.3%) continued to redeem prescriptions for antibiotics within 61–365 days (figure 1).

Women with no usage of antibiotics for UTI before surgery (unexposed)
Of the 1655 women who did not redeem prescription before surgery, 182 (11%) women had a short-term use of antibiotics for UTI after surgery; and of these, 64 women were also long-term users (figure 1). Among unexposed without short-term postoperative use of antibiotics, 171 (10.3%) became long-term postoperative...
users (figure 1). The total number of women with long-term antibiotic use was 235 (14.2%).

Comparison of exposed and unexposed cohorts
Baseline characteristics of exposed and unexposed women are presented in table 1. The most commonly used procedure was MUS accounting for approximately half of the procedures performed in both the exposed and the unexposed group. The most commonly prescribed drugs prior to surgery were sulphamethizol and pivmecillinam. Compared with unexposed women, exposed women tended to be older, to be more frequent oestrogen users and to have higher comorbidity indices. There was no difference in educational level or personal annual income.

The unadjusted OR of a prior antibiotic user being a postoperative short-term and long-term user was 2.8 (95% CI 2.2 to 3.7) and 4.6 (95% CI 3.7 to 5.8), respectively. The adjusted OR of being short-term and long-term user of antibiotics for UTI after surgery was 2.6 (95% CI 2.0 to 3.5) and 4.5 (95% CI 3.5 to 5.7), respectively (table 2). Thus, adjustment for confounders did virtually not change the relative risk estimates. The details from logistic regression models are presented in table 2 showing the impact of each prognostic factor included.

Regarding short-term use, the strongest risk factors were procedure type (rpMUS/others), high comorbidity index and preoperative antibiotic use. Preoperative use of antibiotics for UTI was the strongest risk factor of long-term postoperative use.

Stratified analyses according to the use of oestrogens before surgery showed that among users of oestrogen, the adjusted OR for short-term and long-term use of antibiotics for UTI after surgery increased to 3.3 (95% CI 2.3 to 4.8) and 5.2 (95% CI 3.7 to 7.3), respectively, table 3.

DISCUSSION
Among 2151 women undergoing surgery for UI, nearly one-fourth had redeemed at least one prescription of antibiotics for UTI preoperatively, and among preoperative users nearly half of the women also redeemed prescriptions of antibiotics for UTI within 61–365 days after surgery. Among preoperative users of antibiotics we found a 2–3-fold increased risk of short-term use of antibiotics for UTI after surgery, and a 4–5-fold increased risk of being long-term user. In women not using antibiotics for UTI before surgery only a minor proportion initiated use of antibiotics after surgery.

To ensure that our results were not influenced by effect modification of oestrogen use we stratified our analyses for preoperative use of oestrogen. In both strata we found an increased risk of postoperative antibiotic use for the exposed women. The risk estimates for short-term and long-term use were, however, higher among women using oestrogen preoperatively compared with women without prior oestrogen use.

The proportion of women with concomitant surgery for pelvic organ prolapse in our cohort of women with UI surgery was low, and this was as expected given the current practice in Scandinavia with a conservative approach of addressing the predominant problem of either pelvic organ prolapse or UI in sequential surgery. Thus, our results were not influenced by a mixed cohort with both UI surgery and pelvic organ prolapse surgery.

Our study has several strengths: (1) it is population-based in the sense that this study covers all the relevant surgeries in a well-defined geographic area in Denmark, (2) the source of procedure codes in the NPR has high coverage and validity—the NPR records 99.4% of all discharges from hospitals in Denmark, and the procedures in the NRP have been validated showing a high quality of the data with positive predictive values of 94–100%.34–36

Figure 1 Women (N=2151) with primary surgery for urinary incontinence (UI) and their use of antibiotics for urinary tract infection before and after surgery for UI. Exposed women had redeemed one or more prescriptions of antibiotics within 365 days preceding the date of surgery. Unexposed women had not redeemed prescriptions of antibiotics within 365 days preceding the date of surgery.
prior antibiotic use, thus preventing differential misclassification of the outcome, (7) the antibiotics included in this study are UTI specific and are drugs of choice in Denmark for treating UTI and finally (8) the surgical procedures included have no other indications than UI, which strongly limits the number of alternative interpretations of our findings. Furthermore, the exclusion of antibiotics with other indications than UTI may even have led to an underestimation of the risk of UTI.

There are possible limitations to our study. We have no information on perioperative use of antibiotic, antibiotic given while the patient was still hospitalised, or results of urine culture. A redeemed prescription of antibiotics for UTI does not necessarily equal a UTI, and urine culture is not always performed prior to a prescription. Thus, empiric therapy is possible. To prevent UTI and other postoperative infections a perioperative single-dose of intravenous antibiotic is often used in Denmark. However, perioperative antibiotic use is unlikely to be much different between exposed and unexposed cohorts and will thus not bias our relative risk estimates. In the short-term perspective after surgery we had no knowledge of postoperative catheter usage which is a limitation, especially since postoperative UTI is associated with catheter usage in the postoperative period but again we have no reasons to believe that use of catheters differed among exposed and unexposed cohorts. We were not able to control for all potential confounders such as body mass index, parity, intraoperative bladder perforation or precise menopausal status, but the importance of these factors for the association examined in this study is not clear. We had no data on patient symptomatology, that is, whether stress UI, urgency UI, mixed UI or overactive bladder syndrome were predominant, or on urodynamic study, and it could have been interesting to further examine the users of UTI antibiotics (both before and after surgery) according to the type of UI symptomatology.

It is surprising that among women using antibiotics for UTIs before UI surgery, half of them have a continuing tendency to use these antibiotics after surgery. This is not explained by recurrent UI surgery in the study period of 1 year after surgery as only approximately 5% of women experienced a new surgery in our population. Possible explanations for the continuing tendency to UTI could be a genetic predisposition for UTI, an anatomic predisposition for UTI, or an increased awareness of UTI for both the women and their doctor.

On the basis of the flow chart in our study, we observed a tendency to continuing UI among women with preoperative antibiotic use in short-term and long-term, postoperatively. To our knowledge, this is the largest, and only population-based, study examining the use of antibiotics for UTI in relation to surgery for UI and addressing the risk of short-term and long-term postoperative use of antibiotics for UTI among women with preoperative UTI. In addition, our study provides knowledge about which other factors than preoperative

---

**Table 1** Baseline characteristics of all included women (N=2151) having a primary surgical procedure for UI in Denmark, 1996–2010

<table>
<thead>
<tr>
<th></th>
<th>Exposed* n=496</th>
<th>Unexposed† n=1655</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (±SD), years (at time of first UI surgery)</td>
<td>60.2 (±13.2)</td>
<td>54.2 (±12.4)</td>
</tr>
<tr>
<td>Age groups, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–39</td>
<td>30 (6.1)</td>
<td>182 (11.0)</td>
</tr>
<tr>
<td>40–59</td>
<td>196 (39.5)</td>
<td>911 (55.1)</td>
</tr>
<tr>
<td>60+</td>
<td>270 (54.4)</td>
<td>562 (33.9)</td>
</tr>
<tr>
<td>Procedures, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rpMUS</td>
<td>140 (28.2)</td>
<td>535 (32.3)</td>
</tr>
<tr>
<td>toMUS</td>
<td>222 (44.8)</td>
<td>750 (45.3)</td>
</tr>
<tr>
<td>Bulking</td>
<td>110 (22.2)</td>
<td>250 (15.1)</td>
</tr>
<tr>
<td>Others</td>
<td>24 (4.8)</td>
<td>120 (7.3)</td>
</tr>
<tr>
<td>Concomitant prolapse surgery, n (%)</td>
<td>12 (2.4)</td>
<td>66 (4.0)</td>
</tr>
<tr>
<td>Antibiotics before surgery, n (%)‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfamethizol—J01EB02</td>
<td>299 (60.3)</td>
<td>–</td>
</tr>
<tr>
<td>Pivmecillinam—J01CA08</td>
<td>288 (58.1)</td>
<td>–</td>
</tr>
<tr>
<td>Nitrofurantoin—J01XE01</td>
<td>65 (13.1)</td>
<td>–</td>
</tr>
<tr>
<td>Trimethoprim—J01EA01</td>
<td>45 (9.1)</td>
<td>–</td>
</tr>
<tr>
<td>Mecillinam—J01CA11</td>
<td>0 (0)</td>
<td>–</td>
</tr>
<tr>
<td>Oestrogen users, n (%)§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>211 (42.5)</td>
<td>997 (60.2)</td>
</tr>
<tr>
<td>Yes</td>
<td>285 (57.5)</td>
<td>658 (39.8)</td>
</tr>
<tr>
<td>Comorbidity (CCI), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>298 (60.1)</td>
<td>1214 (73.4)</td>
</tr>
<tr>
<td>1–2</td>
<td>139 (28.0)</td>
<td>381 (23.0)</td>
</tr>
<tr>
<td>3+</td>
<td>59 (11.9)</td>
<td>60 (3.6)</td>
</tr>
<tr>
<td>Educational level, n (%)¶</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic</td>
<td>229 (47.4)</td>
<td>688 (42.3)</td>
</tr>
<tr>
<td>Secondary</td>
<td>170 (35.2)</td>
<td>600 (36.8)</td>
</tr>
<tr>
<td>Higher</td>
<td>84 (17.4)</td>
<td>340 (20.9)</td>
</tr>
<tr>
<td>Annual income, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (1st quartile)</td>
<td>152 (30.7)</td>
<td>385 (23.3)</td>
</tr>
<tr>
<td>Middle (2nd–3rd quartile)</td>
<td>252 (50.8)</td>
<td>825 (49.9)</td>
</tr>
<tr>
<td>High (4th quartile)</td>
<td>92 (18.5)</td>
<td>445 (26.9)</td>
</tr>
<tr>
<td>Year of surgery n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996–2006</td>
<td>106 (21.4)</td>
<td>353 (21.3)</td>
</tr>
<tr>
<td>2007–2008</td>
<td>186 (37.5)</td>
<td>605 (36.6)</td>
</tr>
<tr>
<td>2009–2010</td>
<td>204 (41.1)</td>
<td>697 (42.1)</td>
</tr>
</tbody>
</table>

*Exposed women had redeemed one or more prescriptions of antibiotics within 365 days preceding the date of surgery.
†Unexposed women had not redeemed prescriptions of antibiotics within 365 days preceding the date of surgery.
‡Does not sum up to 100%. Some women redeemed more than one type of the drugs during the time period.
§Women with at least one redeemed prescription of oestrogen within 365 days preceding the date of surgery.
¶Unknown highest attained educational level: 40 women. CCI, Charlson comorbidity index; rpMUS, retropubic mid-urethral sling, toMUS, trans-obturator mid-urethral sling.

---

(3) the access to high-quality data on prescriptions from the OPED that are representative for the Danish population, (4) information on several confounders such as comorbidity and socioeconomic status, (5) complete information on the follow-up period for all included women, (6) outcome data on postoperative antibiotic prescriptions are recorded independently of
antibiotic were important for postoperative antibiotic use for UTI. We found that for short-term use procedure type (rpMUS, others), and high comorbidity were risk factors and for long-term use high comorbidity was a risk factor. Our study also showed that educational level and personal income did not seem to influence the risk of postoperative antibiotic use.

In Denmark, dipstick urine test is a part of the preoperative examination, and surgeons might feel encouraged to treat the women with antibiotics prior to surgery based on dipstick urine test without symptoms or urine culture in an attempt to try to minimise the risk of postoperative UTI.

According to the Danish Programme for the surveillance of antimicrobial consumption and resistance in bacteria from animals, food and humans, the resistance, especially in bacteria other than *Escherichia coli*, has increased during the last years. *E coli* is the most frequent cause of UTIs both in community-acquired and hospital-acquired UTIs.

Our study calls for further studies within this area—studies examining UTI before and after surgery according to different types of UI (stress UI, urgency UI, mixed UI), UTI in relation to surgery in especially postmenopausal women, issues regarding recurrent UTI and UI surgery, and if prophylactic antibiotic use (perioperative intravenous/prolonged oral antibiotics) could reduce the risk of postoperative UTI after UI surgery in a short-term and long-term perspective. Furthermore, it would be interesting to assess the use of similar antibiotics in the background population of women to examine whether there is an increased antibiotic burden associated with surgery for UI.

In conclusion, we found that one in four women undergoing surgery for UI was treated for UTI before surgery, and half of these women continued the tendency of UTI after surgery. In women not using antibiotics for UTI before surgery only a minor proportion initiated use of antibiotics for UTI after surgery.

The strongest risk factor of postoperative use of antibiotics for UTI was the use of these antibiotics before surgery.

### Author affiliations

1. Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
2. Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark
3. Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark
4. Department of Hospital Services and Emergency Management, Danish Health and Medicines Authority, Copenhagen, Denmark
5. Research Unit of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark

### Contributors

All authors have drafted the article, revised it critically for important intellectual content, and approved the final version to be published. All authors are responsible for the study concept and design, and participated in the interpretation of data. RG is the guarantor.

### Funding

This study was funded by (1) Nordic Urogynaecology Association (NUGA) Research Grant. (2) A P Møller and Chastine Mc-Kinney Møller Foundation for General Purposes. (3) Center for Clinical Epidemiology, Odense University Hospital and (4) Region of Southern Denmark.

### Competing interests

None.

### Ethical approval

The study was approved by the Danish Data Protection Agency (no. 2009-41-3564). According to Danish law, ethical review board approval or patient consent are not required for register-based studies.

### Provenance and peer review

Not commissioned; externally peer reviewed.

### Data sharing statement

According to the Danish Data Protection Agency, we are not allowed to share our data from the Danish National Patient Registry. This would require a special approval from both the Danish Data Protection Agency and the Statens Serum Institut who provides the data from the Danish National Patient Registry.

### Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

### REFERENCES

Appendix 1 Surgical procedures according to the Danish Nordic Medico-Statistical Committee

KDG00 = Retropubic suspension of urethra
KDG01 = Percutaneous endoscopic retropubic suspension of urethra
KDG10 = Abdominovaginal suspension of bladder neck
KDG30 = Suprapubic sling urethrocystopexy
KDG31 = Percutaneous endoscopic suprapubic sling
KDG40 = Suprapubic urethrocystopexy
KDG50 = Transabdominal plastic repair of pelvic floor for urinary incontinence
KDG96 = Other operation on urethra or bladder neck for incontinence
KDG97 = Other percutaneous endoscopic operation on urethra or bladder neck for incontinence
KDV20 = Submucous urethral injection
KDV22 = Transluminal endoscopic submucous urethral injection
KLEG00 = Vaginal urethrocystorrhaphy
KLEG10 = Vaginal urethrocystopexy with use of sling
KLEG10A = Vaginal urethrocystopexy with use of sling through foramen obturatum
KLEG20 = Plastic repair of female pelvic floor with levator division
KLEG96 = Other vaginal operation for incontinence